Fundraising Fox
🦊/Companies
Sign in

Pulmonx Corp.

NASDAQ: LUNG

San Jose, US · Delaware corporation · 269 employees on LinkedIn · 6 known investors

Find your way into Pulmonx Corp.

Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery. The company operates in the medical device industry, serving pulmonologists and patients with severe emphysema through a minimally invasive lung treatment.

BiotechHealthtechMedical Devices

Founders & leadership

LC
LAUREN CRISTINAinVP, Finance and Administration
SRSri Radhakrishnan
Sri RadhakrishnaninChief Technology Officer
MB
MICHAEL BAKERinPresident and CEO2009–2014
GE
Glendon E. FrenchChief Executive Officer and Director
DSDerrick Sung
Derrick SunginChief Operating Officer & Chief Financial OfficerExecutive Officer at Aerin Medical
GB
Geoffrey Beran RoseChief Commercial Officer
SR
Srikanth RadhakrishnanChief Science and Technology Officer

Board

DG
DANA G. MEAD, JRBoard director
SS
STEPHEN SALMONinBoard directorGeneral Partner at Latterell Venture Partners
MMMICHAEL MATLY
MICHAEL MATLYin𝕏Investor and Board Member2016–2020Managing Partner at West Capital
SLSTAFFAN LINDSTRAND
STAFFAN LINDSTRANDin𝕏Board directorPartner at HealthCap
RF
RICH FERRARIBoard director

Investors · 6

Band of AngelsSilicon Valley
HealthCapStockholmvia Staffan Lindstrand · board
Kaiser Permanente VenturesSan Francisco · $2M – $5M
Latterell Venture PartnersSan Ramon · $50K – $10M
Ally Bridge GroupreportedNew York
Montreux Equity PartnersreportedSan Francisco · $10M – $20M

Funding

SEC filings, press & company announcements

$201.1M disclosed across 5 rounds · 2012–2026

▶$65.1MraisedApr 2019 · 18 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • STAFFAN LINDSTRANDDirector
  • LAUREN CRISTINAExecutive Officer
  • GLENDON E. FRENCHExecutive Officer, Director
  • RICH FERRARIDirector
  • MICHAEL MATLYDirector
  • STEPHEN SALMONDirector
  • DANA G. MEAD, JRDirector
  • CHARLES CHONDirector
  • OERN STUGEDirector
  • RODNEY PERKINS, M.D.Director
Offering amount
$65.1M
Amount sold
$65.1M
First sale
Apr 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$50MraisedApr 2017 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • GLENDON E. FRENCHExecutive Officer, Director
  • DANA G. MEAD, JRDirector
  • STEPHEN SALMONDirector
  • RODNEY PERKINS, M.D.Director
  • OERN STUGEDirector
  • MICHAEL MATLYDirector
  • LAUREN CRISTINAExecutive Officer
  • STAFFAN LINDSTRANDDirector
  • RICH FERRARIDirector
Offering amount
$50M
Amount sold
$50M
First sale
Jun 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedApr 2014 · 17 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • ANNETTE CAMPBELL-WHITEDirector
  • MARTIN SCHNEIDERExecutive Officer
  • HOWARD PALEFSKYDirector
  • STEVE SALMONDirector
  • MICHAEL BAKERExecutive Officer
  • LAUREN CRISTINAExecutive Officer
  • RODNEY PERKINS, M.D.Executive Officer, Director
  • STAFFAN LINDSTRANDDirector
  • RICH FERRARIDirector
  • DANA MEADDirector
Offering amount
$12M
Amount sold
$10M
First sale
Mar 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedFeb 2012 · 13 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • RICH FERRARIDirector
  • MICHAEL BAKERExecutive Officer, Director
  • HOWARD PALEFSKYDirector
  • STAFFAN LINDSTRANDDirector
  • RODNEY PERKINS, M.D.Director
  • DANA MEADDirector
  • ANNETTE CAMPBELL-WHITEDirector
  • STEVE SALMONDirector
Offering amount
$10M
Amount sold
$10M
First sale
Jan 2012
Incorporated
Corporation, California
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$426.9Mvaluation at IPOOct 2020 · $19.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 1

by search overlap
Medscape131 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Pulmonx Corp. for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Brokerages Set Pulmonx Corporation (NASDAQ:LUNG) PT at $5.58 - Defense Worlddefenseworld.net · Jul 2026Pulmonx to Release Q2 2026 Financial Results July 29 | LUNG Stock Newsstocktitan.net · Jul 2026Pulmonx Corporation Raises $66.0M | Signalbasetrysignalbase.com · May 2026Pulmonx, Inc. Raises $32 Million for Launch of Emphysema Products - BioSpacebiospace.com · Feb 2010Pulmonx News - Pulmonx Raises $32 Million for Launch of Emphysema Productspulmonx.com

Frequently asked questions

What does Pulmonx Corp. do?
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery. The company operates in the medical device industry, serving pulmonologists and patients with severe emphysema through a minimally invasive lung treatment.
Who are Pulmonx Corp.'s investors?
Pulmonx Corp.'s investors include Band of Angels, HealthCap, Kaiser Permanente Ventures, Latterell Venture Partners, Ally Bridge Group, Montreux Equity Partners.
How much funding has Pulmonx Corp. raised?
Pulmonx Corp. has disclosed $201.1M raised across 5 rounds.
Where is Pulmonx Corp. headquartered?
Pulmonx Corp. is headquartered in San Jose, US.